These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18025166)

  • 1. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL; Gough MJ; Weinberg AD
    Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
    Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
    J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
    Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
    Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
    Lee SW; Park Y; Song A; Cheroutre H; Kwon BS; Croft M
    J Immunol; 2006 Oct; 177(7):4464-72. PubMed ID: 16982882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.
    Song A; Tang X; Harms KM; Croft M
    J Immunol; 2005 Sep; 175(6):3534-41. PubMed ID: 16148096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
    Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
    J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
    Amani MF; Rolig AS; Redmond WL
    J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costimulation of CD8 T cell responses by OX40.
    Bansal-Pakala P; Halteman BS; Cheng MH; Croft M
    J Immunol; 2004 Apr; 172(8):4821-5. PubMed ID: 15067059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
    Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
    Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.